Nantes

• APOLLO: A Randomized, Double-Blind, Placebo-Controlled Study of Bitopertin to Evaluate the Efficacy, Safety, and Tolerability in Participant … Ended recruitment
  2024-520407-27-00 5 2025-10-23 X-Linked Protoporphyria (XLP)
• A study to test whether vicadrostat in combination with empagliflozin helps people with chronic kidney disease Ended recruitment
  2024-518457-42-00 4 2025-08-28 chronic kidney disease
• A phase 1/2a multicenter trial to evaluate the safety and immunogenicity of the CD40.Pan.CoV vaccine, adjuvanted or not, as a booster in adu … Ended recruitment
  2024-516767-92-01 1 2025-06-17 Health Participants
• A Phase 3 study to assess the efficacy, safety, and tolerability of itepekimab (anti­IL­33 mAb) in participants with inadequately-controlled … Ended recruitment
  2024-516815-26-00 5 2025-05-30 Chronic rhinosinusitis with nasal polyps
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED STUDY OF PF-06939926 IN DMD Ended recruitment
  2023-508510-42-00 5 2025-03-24 DUCHENNE MUSCULAR DYSTROPHY (DMD)
• DOVIPA, a phase II study evaluating efficacy and safety of DOstarlimab and oral VItamin D3 with folinic acid, 5FU, Irinotecan plus oxalipalt … Ended recruitment
  2023-510004-49-00 4 2025-02-18 non pretreated metastatic PAncreatic Cancer
• A Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in Partic … Ended recruitment
  2023-509588-25-00 4 2025-02-11 Hepatitis B
• A study to test an oral medicine, belumosudil, in combination with corticosteroids in participants at least 12 years of age with newly diagn … Ended recruitment
  2023-505394-32-00 5 2025-02-06 chronic graft versus host disease
• CLINICAL STUDY TO TEST STEM CELLS FOR THE TREATMENT OF LONG-TERM, NON-HEALING VENOUS LEG ULCERS Ended recruitment
  2024-512720-11-00 5 2025-01-16 chronic venous ulcers (CVU)
• A Study to Assess the Effectiveness and Safety of RO7790121 for Induction Therapy in Participants with Moderately to Severely Active Ulcerat … Ended recruitment
  2024-513015-27-00 5 2025-01-09 Moderately to Severely Active Ulcerative Colitis (UC)
• ANRS0407s -LKV.Cov40. A phase 1/2 multicenter, randomized study of the safety and immunogenicity of a sub-unit protein CD40.RBDv bivalent CO … Ended recruitment
  2023-504594-20-00 1 2025-01-06 Healthy volunteers
• A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended recruitment
  2024-513208-32-00 5 2024-12-16 Chronic Spontaneous Urticaria
• REBALANCE UC : impact of Fecal Microbiota Transplantation in ulcerative colitis:a randomized, sham controlled trial Ended recruitment
  2024-511863-27-01 10 2024-12-06 Adult patients with ulcerative colitis diagnosed for at least 3 months
• L19IL2/L19TNF in skin cancer patients Ended recruitment
  2024-518531-10-00 4 2024-11-26 Phase II, open label, multicentric, proof-of-principle basket trial in
• A multi-center, open-label extension study of subcutaneous secukinumab to evaluate the long-term safety and tolerability in polymyalgia rheu … Ended recruitment
  2023-508077-85-00 5 2024-11-19 Polymyalgia Rheumatica
• A randomized, controlled study to evaluate LNP023 (iptacopan) in patients with active ANCA-associated vasculitis. Ended recruitment
  2023-510525-15-00 4 2024-11-18 active antineutrophilic cytoplasmic antibody (ANCA) associated vasculi
• Transmural Healing and Disease Modifying Effect of Guselkumab in Crohn’s Disease Patients Ended recruitment
  2023-504040-34-01 5 2024-11-12 Crohn’s Disease
• PRODIGE 49 - OSCAR: Systemic oxaliplatin or in intra-arterial chemotherapy combined with LV5FU2 ± Irinotecan, and targeted therapy, in first … Ended recruitment
  2024-518553-41-00 5 2024-11-08 colon cancer and rectal with liver metastasis
• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended recruitment
  2023-508636-61-00 5 2024-10-24 Crohn’s Disease
• A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, … Ended recruitment
  2023-505739-12-01 5 2024-09-30 Chronic Inducible Urticaria (CINDU)
• A Phase III study to investigate the efficacy and safety of anifrolumab in adults with chronic and/or subacute cutaneous lupus erythematosus Ended recruitment
  2023-503692-24-00 5 2024-09-25 Cutaneous Lupus Erythematosus
• A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer Ended recruitment
  2024-511038-11-00 4 2024-09-24 advanced prostate cancer
• A study to determine if ravulizumab can help preserve kidney function in adults with immunoglobulin A nephropathy (IgAN) Ended recruitment
  2023-507851-31-00 5 2024-09-23 Immunoglobulin A Nephropathy (IgAN)
• A Study to Evaluate the Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis Ended recruitment
  2024-511260-84-00 4 2024-09-03 Atopic Dermatitis

Showing 457–480 of 787 trials